Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04408937 | The Purpose of This Study is to Investigate Safety and Tolerability of Tropifexor. | PHASE1 | COMPLETED | 89 | — | — | May 29, 2020 | Nov 4, 2020 | Feb 9, 2022 | 10 | United States |
| Arm | Type | Description |
|---|---|---|
| tropifexor AM 200 micrograms and Placebo (PM) | EXPERIMENTAL | Tropifexor 200 μg (AM) and Placebo (PM) once daily each |
| tropifexor PM 200 micrograms and Placebo (AM) | EXPERIMENTAL | Tropifexor 200 μg (PM) and Placebo (AM) once daily each |
| Name | Type | Description |
|---|---|---|
| triopifexor | DRUG | Tropifexor as a dry blend in hard gelatin capsules for oral administration |
| Placebo | DRUG | Placebo capsules for oral administration |
Inclusion Criteria: -Presence of Liver Disease Exclusion Criteria: * Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days, whichever is longer; or longer if required by local regulations. * Subjects taking the following medicines UN...